666
Participants
Start Date
March 31, 2000
Primary Completion Date
April 30, 2001
Study Completion Date
April 30, 2001
biphasic insulin aspart 50
Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
biphasic insulin aspart 70
Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
biphasic human insulin 30
Administered subcutaneously (s.c., under the skin), twice a day
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Edegem
Novo Nordisk Investigational Site, Genk
Novo Nordisk Investigational Site, Liège
Novo Nordisk Investigational Site, Jumet
Novo Nordisk Investigational Site, Aalst
Novo Nordisk Investigational Site, Narbonne
Novo Nordisk Investigational Site, Marseille
Novo Nordisk Investigational Site, Caen
Novo Nordisk Investigational Site, La Rochelle
Novo Nordisk Investigational Site, Dijon
Novo Nordisk Investigational Site, Nîmes
Novo Nordisk Investigational Site, Bagnols-sur-Cèze
Novo Nordisk Investigational Site, Toulouse
Novo Nordisk Investigational Site, Bordeaux
Novo Nordisk Investigational Site, Grenoble
Novo Nordisk Investigational Site, Reims
Novo Nordisk Investigational Site, Dommartin-lès-Toul
Novo Nordisk Investigational Site, Lorient
Novo Nordisk Investigational Site, Nevers
Novo Nordisk Investigational Site, Roubaix
Novo Nordisk Investigational Site, Strasbourg
Novo Nordisk Investigational Site, Colmar
Novo Nordisk Investigational Site, Lyon
Novo Nordisk Investigational Site, Mâcon
Novo Nordisk Investigational Site, Le Creusot
Novo Nordisk Investigational Site, Paris
Novo Nordisk Investigational Site, Paris
Novo Nordisk Investigational Site, Avignon
Novo Nordisk Investigational Site, Nanterre
Novo Nordisk Investigational Site, Amiens
Novo Nordisk Investigational Site, Orléans
Novo Nordisk Investigational Site, Saint-Etienne
Novo Nordisk Investigational Site, Dublin
Novo Nordisk Investigational Site, Arnhem
Novo Nordisk Investigational Site, Beverwijk
Novo Nordisk Investigational Site, Einhoven
Novo Nordisk Investigational Site, Dublin
Novo Nordisk Investigational Site, Dublin
Novo Nordisk Investigational Site, 's-Hertogenbosch
Novo Nordisk Investigational Site, Alkmaar
Novo Nordisk Investigational Site, Amersfoort
Novo Nordisk Investigational Site, Delft
Novo Nordisk Investigational Site, Hengelo
Novo Nordisk Investigational Site, Rotterdam
Novo Nordisk Investigational Site, Rotterdam
Novo Nordisk Investigational Site, The Hague
Novo Nordisk Investigational Site, Ayr
Novo Nordisk Investigational Site, Ayrsh
Novo Nordisk Investigational Site, Bath
Novo Nordisk Investigational Site, Birmingham
Novo Nordisk Investigational Site, Brighton
Novo Nordisk Investigational Site, Coventry
Novo Nordisk Investigational Site, Dundee
Novo Nordisk Investigational Site, Edgware
Novo Nordisk Investigational Site, Edinburgh
Novo Nordisk Investigational Site, Exeter
Novo Nordisk Investigational Site, Glasgow
Novo Nordisk Investigational Site, Haywards Heath
Novo Nordisk Investigational Site, Ipswich
Novo Nordisk Investigational Site, Leeds
Novo Nordisk Investigational Site, Leicester
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Nottingham
Novo Nordisk Investigational Site, Paisley
Novo Nordisk Investigational Site, Poole
Novo Nordisk Investigational Site, Rugby
Novo Nordisk Investigational Site, Scunthorpe
Novo Nordisk Investigational Site, Southampton
Novo Nordisk Investigational Site, Sunderland
Novo Nordisk Investigational Site, Swansea
Novo Nordisk Investigational Site, Watford
Novo Nordisk Investigational Site, Whiston
Lead Sponsor
Novo Nordisk A/S
INDUSTRY